Abivax S.A.
FRValuation Metrics
Abivax S.A.'s Market Cap is $6.76B. At end of 2025 it was $919M. Ranked #1113 of 3,118 in US market (top 36%), #359 of 1,474 on NASDAQ (top 24%), #59 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $6.76B | US#1,113/3,118 Sec#59/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-380M | US—/3,118 Sec—/265 |
| Total Assets | $686M | US#2,634/3,118 Sec#133/265 |
| Net Assets | $535M | US#2,181/3,118 Sec#101/265 |
| Employees | 80 | US#2,649/3,118 Sec#189/265 |
| Value | ||
| P/B | 12.65x | US#2,695/3,118 Sec#200/265 |
| FCF Yield | -2.60% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -71.04% | US#2,746/3,118 Sec#190/265 |
| ROA | -55.34% | US#2,998/3,118 Sec#223/265 |
| Financial Health | ||
| Debt Ratio | 28.37% | US#311/3,118 Sec#100/265 |
| Total Debt | $54M | US#2,585/3,118 Sec#153/265 |
| FCF | $-176M | US#2,752/3,118 Sec#198/265 |
| Cash | $607M | US#950/3,118 Sec#47/265 |
| Current Ratio | 8.75x | US#290/3,118 Sec#86/265 |
| Performance | ||
| 1Y Return | -17.14% | US#2,332/3,118 Sec#183/265 |
| 1M Return | -8.62% | US#2,566/3,118 Sec#192/265 |
| From 52W High | -42.98% | US#2,391/3,118 Sec#170/265 |
| 1Y MDD | -50.11% | US#2,399/3,118 Sec#164/265 |
| Trading | ||
| Volume | 702,702 shares | US#1,674/3,118 Sec#163/265 |
| Trading Value | $60M | US#1,081/3,118 Sec#64/265 |
| Per Share | ||
| EPS | $-4.76 | US—/3,118 Sec—/265 |
| BPS | $6.71 | US#2,118/3,118 Sec#103/265 |
Company Info
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.